INmune Bio (NASDAQ:INMB) Research Coverage Started at Raymond James

Raymond James initiated coverage on shares of INmune Bio (NASDAQ:INMB) in a report released on Friday morning, MarketBeat.com reports. The firm issued an outperform rating and a $18.00 target price on the stock.

Separately, Scotiabank began coverage on INmune Bio in a research note on Thursday, August 22nd. They set a sector outperform rating and a $22.00 price target for the company.

INmune Bio Trading Up 3.3 %

Shares of INmune Bio stock opened at $5.39 on Friday. The company has a 50-day moving average of $6.73 and a two-hundred day moving average of $8.75. INmune Bio has a 12-month low of $4.81 and a 12-month high of $14.74. The stock has a market cap of $106.62 million, a PE ratio of -2.81 and a beta of 1.86.

INmune Bio (NASDAQ:INMB) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.13. INmune Bio had a negative return on equity of 103.56% and a negative net margin of 26,333.59%.

Insider Activity

In related news, CEO Raymond Joseph Tesi acquired 15,380 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was purchased at an average cost of $6.38 per share, for a total transaction of $98,124.40. Following the transaction, the chief executive officer now directly owns 1,554,106 shares of the company’s stock, valued at approximately $9,915,196.28. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CEO Raymond Joseph Tesi acquired 15,380 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were acquired at an average price of $6.38 per share, with a total value of $98,124.40. Following the completion of the purchase, the chief executive officer now directly owns 1,554,106 shares in the company, valued at $9,915,196.28. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, CFO David J. Moss acquired 7,690 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were bought at an average price of $6.38 per share, with a total value of $49,062.20. Following the transaction, the chief financial officer now owns 1,275,869 shares in the company, valued at approximately $8,140,044.22. The disclosure for this purchase can be found here. Insiders have acquired 33,070 shares of company stock worth $200,087 over the last ninety days. 35.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On INmune Bio

Several institutional investors and hedge funds have recently modified their holdings of the company. CVI Holdings LLC purchased a new stake in INmune Bio in the 2nd quarter worth approximately $5,260,000. Marshall Wace LLP grew its position in shares of INmune Bio by 332.1% in the second quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock valued at $1,022,000 after purchasing an additional 89,091 shares during the period. Rhumbline Advisers acquired a new position in INmune Bio in the second quarter valued at $121,000. Bank of New York Mellon Corp lifted its position in INmune Bio by 124.6% during the second quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock worth $517,000 after buying an additional 32,511 shares during the period. Finally, Westside Investment Management Inc. boosted its stake in INmune Bio by 31.8% in the 2nd quarter. Westside Investment Management Inc. now owns 45,340 shares of the company’s stock worth $400,000 after buying an additional 10,950 shares during the last quarter. Hedge funds and other institutional investors own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.